{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Small+Intestine+Cancer&page=15", "query": { "condition": "Advanced Small Intestine Cancer", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 371, "total_pages": 38, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Small+Intestine+Cancer&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Small+Intestine+Cancer&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T19:54:38.474Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06147037", "title": "A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Colorectal Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "FPI-2053", "type": "DRUG" }, { "name": "[111In]-FPI-2107", "type": "DRUG" }, { "name": "[225Ac]-FPI-2068", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 13, "start_date": "2024-07-31", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-30T19:54:38.474Z", "location_count": 6, "location_summary": "Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06147037" }, { "nct_id": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Solid Tumors" ], "interventions": [ { "name": "SBT6050", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Silverback Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2020-07-27", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-10-30T19:54:38.474Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460456" }, { "nct_id": "NCT07094113", "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "KRAS Altered Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "AMG 410", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 434, "start_date": "2025-07-31", "completion_date": "2031-04-20", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-30T19:54:38.474Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07094113" }, { "nct_id": "NCT06730750", "title": "A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BMS-986490", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2025-02-12", "completion_date": "2029-12-09", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-30T19:54:38.474Z", "location_count": 4, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06730750" }, { "nct_id": "NCT05585034", "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Melanoma Excluding Uveal Melanoma", "Non-small Cell Lung Cancer, Squamous or Non-squamous", "Urothelial Carcinoma", "Renal Cell Carcinoma, Clear Cell", "Castration-resistant Prostate Cancer", "Ovarian Cancer, Epithelial", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "XmAb®808", "type": "BIOLOGICAL" }, { "name": "Keytruda® (pembrolizumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2022-12-14", "completion_date": "2025-05-20", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-10-30T19:54:38.474Z", "location_count": 12, "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585034" }, { "nct_id": "NCT01202409", "title": "CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Cancer" ], "interventions": [ { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2010-11-02", "completion_date": "2018-07-03", "has_results": true, "last_update_posted_date": "2020-02-21", "last_synced_at": "2026-10-30T19:54:38.474Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01202409" }, { "nct_id": "NCT07776353", "title": "Understanding New Cachexia Subtypes Through Observational Epidemiological Research", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Pancreatic Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Colorectal Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Electronic health record review", "type": "OTHER" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Physical functions assessments", "type": "OTHER" }, { "name": "Positron Emission Tomography (PET)", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2023-04-05", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-30T19:54:38.474Z", "location_count": 1, "location_summary": "Pleasanton, California", "locations": [ { "city": "Pleasanton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07776353" }, { "nct_id": "NCT06051695", "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "NSCLC", "Non Small Cell Lung Cancer", "NSCLC, Recurrent", "Non-Small Cell Squamous Lung Cancer", "Pancreas Cancer", "Pancreatic Neoplasm", "Colorectal Adenocarcinoma", "CRC", "Colon Cancer", "Rectal Cancer", "Cancer", "Ovarian Cancer", "Ovarian Neoplasms", "Mesothelioma", "Mesothelioma, Malignant", "Ovary Cancer", "Lung Cancer", "MESOM" ], "interventions": [ { "name": "A2B694", "type": "BIOLOGICAL" }, { "name": "A2B543", "type": "BIOLOGICAL" }, { "name": "xT CDx with HLA-LOH Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 474, "start_date": "2024-04-03", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-30T19:54:38.474Z", "location_count": 12, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06051695" }, { "nct_id": "NCT05651022", "title": "Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "HCC - Hepatocellular Carcinoma", "CRC (Colorectal Cancer)", "Pancreatic Adenocarcinoma", "NSCLC Non-small Cell Lung Cancer", "Squamous Cell Cancer of the Head and Neck", "UC (Urothelial Cancer)", "MSI-H Cancer" ], "interventions": [ { "name": "Decoy20", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indaptus Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2023-02-28", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-30T19:54:38.474Z", "location_count": 12, "location_summary": "Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05651022" }, { "nct_id": "NCT03000179", "title": "Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2017-03-03", "completion_date": "2021-08-03", "has_results": true, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-10-30T19:54:38.474Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03000179" } ] }